文献速递前列腺癌

是否应仅行磁共振靶向穿刺?1,032例前列腺穿刺经验

Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.
PubMed 文献 · J Urol · 2018-04-19

该研究纳入1,032例因疑诊前列腺癌行重复饱和穿刺的男性,中位年龄63岁、中位PSA 8.6 ng/ml,穿刺前均行3.0T多参数磁共振(mpMRI),对PI-RADS≥3病灶加做靶向融合穿刺。饱和穿刺、PI-RADS≥3靶向穿刺、PI-RADS≥4靶向穿刺分别检出95.6%、83.8%、60.3%的临床显著前列腺癌(p<0.0001)。以mpMRI作分诊可分别豁免49.3%(PI-RADS≥3)与73.6%(PI-RADS≥4)的穿刺,但需告知16.2%与39.7%的假阴性率。

要点

  • mpMRI可将约50%的重复穿刺转为不必要(PI-RADS≥3为切点时)。
  • 仅行PI-RADS≥3靶向穿刺会漏诊16.2%的临床显著前列腺癌。
  • 仅行PI-RADS≥4靶向穿刺漏诊率达39.7%,告知假阴性很重要。

核心结论

  • 多参数磁共振可显著减少不必要的重复前列腺穿刺,但仅行靶向穿刺存在不可忽视的临床显著前列腺癌假阴性。

研究设计与样本

  • 2011年1月至2018年2月单中心回顾性研究,1,032例因疑诊前列腺癌行重复饱和前列腺穿刺的男性,中位年龄63岁,中位PSA 8.6 ng/ml。
  • 所有患者穿刺前接受3.0T盆腔多参数磁共振,对PI-RADS≥3病灶加做靶向融合穿刺,以饱和穿刺为参考标准。

主要发现

  • 1,032例中372例(36%)检出T1c前列腺癌,其中272例(73.1%)为临床显著前列腺癌。
  • 饱和穿刺、PI-RADS≥3靶向融合穿刺、PI-RADS≥4靶向融合穿刺分别诊断95.6%、83.8%、60.3%的临床显著前列腺癌(p<0.0001)。
  • 饱和穿刺漏诊12/272(4.5%),PI-RADS≥3与≥4靶向融合穿刺分别漏诊44/272(16.2%)与108/272(39.7%)(p<0.0001)。
  • 以mpMRI作分诊,PI-RADS≥3与≥4切点分别可豁免49.3%与73.6%的患者穿刺。

关键数值与推荐

  • 临床显著前列腺癌检出率:饱和穿刺95.6% vs PI-RADS≥3靶向穿刺83.8% vs PI-RADS≥4靶向穿刺60.3%(p<0.0001)。
  • 临床显著前列腺癌漏诊率:饱和穿刺4.5%(12/272) vs PI-RADS≥3靶向穿刺16.2%(44/272) vs PI-RADS≥4靶向穿刺39.7%(108/272)(p<0.0001)。
  • mpMRI分诊可豁免穿刺比例:PI-RADS≥3为49.3%,PI-RADS≥4为73.6%。

临床怎么用

  • 对重复穿刺人群可先用mpMRI分诊,以减少约半数不必要的穿刺。
  • 若考虑仅行靶向穿刺,须向患者说明PI-RADS≥3与≥4对应的16.2%与39.7%临床显著前列腺癌假阴性率。

局限性

  • 单中心回顾性设计,以重复饱和穿刺为参考标准。
  • 未报告靶向穿刺与饱和穿刺联合策略的检出数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the diagnostic accuracy of multiparametric magnetic resonance imaging to diagnose clinically significant prostate cancer and compared it with the diagnostic accuracy of transperineal saturation prostate biopsy. MATERIALS AND METHODS: From January 2011 to February 2018 repeat saturation prostate biopsy (the reference test) was done due to suspicion of cancer in 1,032 men with a median age of 63 years in whom median prostate specific antigen was 8.6 ng/ml. All patients underwent 3.0 Tesla pelvic multiparametric magnetic resonance imaging before saturation prostate biopsy. Additional targeted fusion prostate biopsy was done of lesions with a PI-RADS™ (Prostate Imaging Reporting and Data System) score of 3 or greater. RESULTS: T1c prostate cancer was found in 372 of the 1,032 patients (36%). Of these cases 272 (73.1%) were classified as clinically significant prostate cancer. Saturation prostate biopsy vs targeted fusion prostate biopsy and a PI-RADS score of 3 or greater vs targeted fusion prostate biopsy and a PI-RADS score of 4 or greater diagnosed 95.6% vs 83.8% vs 60.3% of clinically significant prostate cancers (p <0.0001). Saturation prostate biopsy missed 12 of 272 clinically significant prostate cancers (4.5%) vs 44 (16.2%) and 108 of 272 (39.7%) missed by targeted fusion prostate biopsy and a PI-RADS score of 3 or greater and a score of 4 or greater, respectively (p <0.0001). As a triage test multiparametric magnetic resonance imaging would have spared 49.3% vs 73.6% of patients using a PI-RADS cutoff of 3 or greater vs 4 or greater. CONCLUSIONS: Multiparametric magnetic resonance imaging could significantly reduce the number of unnecessary repeat prostate biopsies in about 50% of cases in which a PI-RADS score of 3 or greater is used. At the same time patients should be informed of the 16.2% and 39.7% false-negative rates of clinically significant prostate cancer for targeted fusion prostate biopsy of PI-RADS 3 or greater and 4 or greater lesions, respectively.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Pepe P, Garufi A, Priolo GD, et al. Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy. J Urol. 2018. PMID: 29679618. doi:10.1016/j.juro.2018.04.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。